Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.59 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.57 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.57 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.53 |
| ▸ | GAK | O14976 | 1/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.47 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.47 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23999350 | 1.00 | KDR (0.59) | KDRPKN1PKN2MAPKAPK2GAK | |
| SCHEMBL23999449 | 0.93 | MAPKAPK2 (0.52) | KDRPKN1PKN2MAPKAPK2GAK | |
| SCHEMBL23999513 | 0.93 | MAPKAPK2 (0.52) | KDRPKN1PKN2MAPKAPK2GAK | |
| SCHEMBL30287670 | 0.93 | KDR (0.58) | KDRPKN1PKN2MAPKAPK2CSNK1A1 | |
| SCHEMBL24003905 | 0.93 | KDR (0.58) | KDRPKN1PKN2MAPKAPK2CSNK1A1 | |
| SCHEMBL24006108 | 0.93 | KDR (0.58) | KDRPKN1PKN2MAPKAPK2CSNK1A1 | |
| SCHEMBL24006229 | 0.92 | KDR (0.52) | KDRPKN1PKN2MAPKAPK2GAK | |
| SCHEMBL23999398 | 0.91 | KDR (0.49) | KDRPKN1PKN2MAPKAPK2CSNK1A1 | |
| SCHEMBL23999408 | 0.89 | MAPKAPK2 (0.49) | KDRPKN1PKN2MAPKAPK2GAK | |
| SCHEMBL23999984 | 0.87 | MAPKAPK2 (0.51) | KDRPKN1PKN2MAPKAPK2GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| WO-2023081845-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081854-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2021226477-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021226519-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | KDR 3271/4885PKN1 781/4885PKN2 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.